Antibodies to the major linear neutralizing domains of cytomegalovirus glycoprotein B among natural seropositives and CMV subunit vaccine recipients

Viral Immunology

Volumn 13, Issue 3, 2000, Pages 329-341

  Marshall, G S ^a   Li, M ^a   Stout, G G ^a   Louthan, M V ^a   Duliege, A M ^a   Burke, R L ^a   Hunt, L A ^a  

^a University of Louisville School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DELTA GLYCOPROTEIN B ANTIBODY; GENE PRODUCT; UNCLASSIFIED DRUG; VIRUS PROTEIN; VIRUS VACCINE;

ANTIBODY TITER; ARTICLE; CYTOMEGALOVIRUS; ENZYME LINKED IMMUNOSORBENT ASSAY; NONHUMAN; PROTEIN DOMAIN; PROTEIN GLYCOSYLATION; PROTEIN MODIFICATION; SERODIAGNOSIS; VIRUS NEUTRALIZATION;

CUCUMBER MOSAIC VIRUS; CYTOMEGALOVIRUS; DNA VIRUSES; HUMAN HERPESVIRUS 5; UNIDENTIFIED BACULOVIRUS;

EID: 0033803010     PISSN: 08828245     EISSN: None     Source Type: Journal    
DOI: 10.1089/08828240050144653     Document Type: Article

References (54)

1. Different antibody responses to a neutralizing epitope of human cytomegalovirus glycoprotein B among seropositive individuals
2. Structural domains involved in human cytomegalovirus glycoprotein B-mediated cell-cell fusion
3. Virus-specific antibody responses in mothers and their newborn infants with asymptomatic congenital cytomegalovirus infections
4. Receptor-binding properties of a soluble form of human cytomegalovirus glycoprotein B
5. The B-lymphocyte system
6. Induction of complement-dependent and -independent neutralizing antibodies by recombinant-derived human cytomegalovirus gp55-116 (gB)
7. Processing of the gp55-116 envelope glycoprotein complex of human cytomegalovirus
8. Cell surface expression of human cytomegalovirus (CMV) gp55-gp116 (gB): Use of CMV-recombinant vaccinia virus-infected cells in analysis of the human neutralizing antibody response
9. Analysis of interstrain variation in cytomegalovirus glycoprotein B sequences encoding neutralization-related epitopes
10. Comparative analysis of sequence variation in gp116 and gp55 components of glycoprotein B of human cytomegalovirus
11. Identification of the human cytomegalovirus glycoprotein B gene and induction of neutralizing antibodies via its expression in recombinant vaccinia virus
12. Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune responses in human volunteers
13. Preclinical evaluation of an ALVAC (canarypox)-human cytomegalovirus glycoprotein B vaccine candidate
14. High expression of human cytomegalovirus (CMV)-gB protein in cells infected with a vaccinia-gB recombinant: The importance of the gB protein in CMV immunity
15. Immune responses to isolated human cytomegalovirus envelope glycoproteins
16. Adaptor plasmids simplify the insertion of foreign DNA into helper-independent retroviral vectors
17. Retrovirus-expressed hemagglutinin protects against lethal influenza virus infections
18. Distribution of linear antigenic sites on glycoprotein gp55 of human cytomegalovirus
19. An ELISA using recombinant proteins for the detection of neutralizing antibodies against human cytomegalovirus
20. Human immune responses to major human cytomegalovirus glycoprotein complexes
21. An adenovirus recombinant that expresses the human cytomegalovirus major envelope glycoprotein and induces neutralizing antibodies
22. Cytomegalovirus vaccines
23. Processing of human cytomegalovirus glycoprotein-B in recombinant adenovirus-infected cells
24. Antibodies to recombinant-derived glycoprotein B after natural human cytomegalovirus infection correlate with neutralizing activity
25. Glycoprotein gp116 of human cytomegalovirus contains epitopes for strain-common and strain-specific antibodies
26. Humoral immune response to functional regions of human cytomegalovirus glycoprotein B
27. Disulfide bonds of herpes simplex virus type 2 glycoprotein gB
28. Evidence for a phosphorylation site in cytomegalovirus glycoprotein B
29. Cytomegalovirus glycoprotein B-specific antibody analysis using electrochemiluminescence detection-based techniques
30. Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB) as determined with human monoclonal antibodies
31. A subunit cytomegalovirus vaccine based on recombinant envelope glycoprotein B and a new adjuvant
32. Assembly of conformation-dependent neutralizing domains of human cytomegalovirus glycoprotein B
33. Enzyme-linked immunosorbent assay for rapid measurement of serum neutralizing activity against human cytomegalovirus
34. Antibody response to human cytomegalovirus glycoproteins gB and gH after natural infection in humans
35. Constitutive expression of human cytomegalovirus glycoprotein B (gpUL55) with mutagenized carboxyl-terminal hydrophobic domains
36. Sequence variation within neutralizing epitopes of the envelope glycoprotein B of human cytomegalovirus: Comparison of isolates from renal transplant recipients and AIDS patients
37. The humoral immune response against human cytomegalovirus is characterized by a delayed synthesis of glycoprotein-specific antibodies
38. Antibodies specific for the antigenic domain 1 of glycoprotein B (gpUL55) of human cytomegalovirus bind to different substructures
39. A fifth human cytomegalovirus glycoprotein B genotype
40. Human cytomegalovirus Towne glycoprotein B is processed by proteolytic cleavage
41. Sequence requirements for proteolytic processing of glycoprotein B of human cytomegalovirus
42. Preparation of human monoclonal antibodies against a cytomegalovirus glycoprotein complex of 130 and 55 kDa
43. Function of human cytomegalovirus glycoprotein B: Syncytium formation in cells constitutively expressing gB is blocked by virus-neutralizing antibodies
44. Glycoprotein H of human cytomegalovirus is a major antigen for the neutralizing humoral immune response
45. Epitope-specific distribution of IgG subclasses against antigenic domains on glycoproteins of human cytomegalovirus
46. Proteolytic processing of human cytomegalovirus glycoprotein gB (gpUL55) is mediated by the human endoprotease furin
47. Immune response to neutralizing epitope on human cytomegalovirus glycoprotein B in Japanese: Correlation of serologic response with HLA-type
48. A continuous sequence of more than 70 amino acids is essential for antibody binding to the dominant antigenic site of glycoprotein gp58 of human cytomegalovirus
49. Mucosal antibodies to human cytomegalovirus glycoprotein B occur following both natural infection and immunization with human cytomegalovirus vaccines
50. Structural and immunological characterization of human cytomegalovirus gp55-116 (gB) expressed in insect cells
51. Mutations in the carboxyl-terminal hydrophobic sequence of human cytomegalovirus glycoprotein B alter transport and protein chaperone binding